Company: ABUS
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001447028-25-000126
Chunk: 22

Company: Arbutus Biopharma Corp
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 22
---
,857 4,616 (1,963)— — 2,653 Issuance of common shares pursuant to ESPP44,541 173 (42)— — 131 Issuance of common shares upon vesting of RSUs580,584 1,518 (1,518)— — — Unrealized loss on available-for-sale securities— — — — (31)(31)Net loss— — — (24,526)— (24,526)Balance March 31, 2025191,481,474 $1,416,332 $82,089 $(1,371,098)$(48,166)$79,157 Stock-based compensation expense— — 864 — — 864 Issuance of common shares pursuant to exercise of options160,037 778 (325)— — 453 Unrealized loss on available-for-sale securities— — — — (21)(21)Net income— — — 2,523 — 2,523 Balance June 30, 2025191,641,511 $1,417,110 $82,628 $(1,368,575)$(48,187)$82,976 Stock-based compensation expense— — 1,263 — — 1,263 Issuance of common shares pursuant to exercise of options296,202 1,371 (577)— — 794 Issuance of common shares pursuant to ESPP15,952 79 (29)— — 50 Unrealized gain on available-for-sale securities— — — — 58 58 Net loss— — — (7,742)— (7,742)Balance September 30, 2025191,953,665 $1,418,560 $83,285 $(1,376,317)$(48,129)$77,399 

See accompanying notes to the condensed consolidated financial statements.

3

ARBUTUS BIOPHARMA CORPORATION

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

(In thousands of U.S. Dollars, except share amounts)

Common Shares Number of SharesShare CapitalAdditional Paid-In CapitalDeficitAccumulated Other Comprehensive LossTotal Stockholders' EquityBalance December 31,